Aristotelis Nastos

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

fasciotens is a dynamic medical device start-up founded by surgeons for surgeons with the goal of improving open abdomen therapy. Our first product fasciotens®Abdomen was intensively developed for new indications, so that today fasciotens®Hernia and fasciotens®Pediatric are available in addition to fasciotens®Abdomen. The innovative fasciotens products use a patented, tissue-sparing technique to apply vertical traction to the fasciae of the abdominal wall, thus creating the conditions for direct abdominal wall closure in cases of open abdomens, complex hernias as well as abdominal wall defects of newborns. For more information, please feel free to visit our website or contact us directly at info@fasciotens.de. We look forward to hearing from you!

As a Siemens Healthineers company, NEO New Oncology GmbH is a dynamically growing company offering complete solutions for molecular tumor profiling in cancer diagnostics and clinical research. NEO’s product range comprises streamlined assays, optimized bioinformatics, user friendly software for data interpretation and tailor made service packages enabling customers to provide meaningful results in a timely manner. NEO New Oncology is constantly optimizing its product portfolio and actively developing strong partnerships with pathologies, research institutes and industry.

DIREVO Biotech AG is a biotechnology company based out of 1Nattermannallee, Cologne, North Rhine-Westphalia, Germany.

We put health at the heart of our work. Biomed is a leading Swiss early-stage VC at the center of European biotech. We build companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality - as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient’s lives.

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

fasciotens is a dynamic medical device start-up founded by surgeons for surgeons with the goal of improving open abdomen therapy. Our first product fasciotens®Abdomen was intensively developed for new indications, so that today fasciotens®Hernia and fasciotens®Pediatric are available in addition to fasciotens®Abdomen. The innovative fasciotens products use a patented, tissue-sparing technique to apply vertical traction to the fasciae of the abdominal wall, thus creating the conditions for direct abdominal wall closure in cases of open abdomens, complex hernias as well as abdominal wall defects of newborns. For more information, please feel free to visit our website or contact us directly at info@fasciotens.de. We look forward to hearing from you!

Gründerfonds Ruhr is a private venture capital fund driving innovation in the Ruhr area by investing in new technologies impacting a broad range of industries. We deploy the capital, the business expertise and the industry access from leading international corporations who share our goal of building Ruhr-based start-ups with transforming ideas. Our objective is to be the institutional investor of choice for founders and become a trusted partner with the resources to catapult young companies to their next stage of development and commercial success. Our long-term vision is to thereby boost entrepreneurial spirit in our region. Key sectors include chemicals & new materials, energy & industrial sector, life sciences & healthcare, logistics & retail and the digital economy. Our current portfolio consists of Abalos Therapeutics, DIMATE, Emergence Therapeutics, Fasciotens, Masterplan.com and talpasolutions. For further information: www.gruenderfonds-ruhr.com